Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility


NEW YORK, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has successfully refinanced its existing senior debt facility with a new US$90 million five year facility provided by funds managed by Oaktree Capital Management, L.P. (“Oaktree”).

The rest is here:
Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility

Related Posts